DOI: https://doi.org/10.14710/jbtr.v11i2.26156

VEGF mRNA Expression in Epithelial Ovarian Cancer: Correlation with rs699947 Gene Variant

1Department of Medical Biology, Faculty of Medicine and Health Science, Universitas Sultan Ageng Tirtayasa, Indonesia

2Department of Medical Biology, Faculty of Medicine, Universitas Indonesia, Indonesia

3Department of Histology, Faculty of Medicine, Universitas Indonesia, Indonesia

4 Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, Indonesia

View all affiliations
Received: 10 Mar 2025; Accepted: 7 Aug 2025; Available online: 31 Aug 2025; Published: 31 Aug 2025.
Open Access Copyright (c) 2025 Journal of Biomedicine and Translational Research
Creative Commons License This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Citation Format:
Abstract

Background: Angiogenesis is the formation of new blood vessels, is crucial for cancer growth and metastasis, including in epithelial ovarian cancer (EOC). Vascular Endothelial Growth Factor (VEGF) regulates angiogenesis, and its elevated mRNA expression is linked to poor prognosis in cancer. Genetic variations, such as the rs699947 polymorphism in the VEGF gene, can affect VEGF expression and contribute to cancer progression.

Objective: The primary aim of this study is to examine the distribution of the VEGF rs699947 polymorphism and its correlation with VEGF mRNA expression levels in patients with low-grade and high-grade EOC at Dr. Cipto Mangunkusumo Hospital, Indonesia.

Methods: This research is a cross-sectional analysis involving 65 normal female whole blood samples and a total of 80 ovarian cancer biopsy samples, including 15 ovarian cysts as expression calibrators, along with 36 low-grade and 29 high-grade EOC samples. The distribution of genotypes and alleles of the VEGF rs699947 polymorphism was assessed through ARMS PCR analysis, while VEGF mRNA expression was quantified using real-time qPCR.

Results: Significant differences were observed in both genotype (p<0,01) and allele (p=0,000) distributions between the normal and cases group. The relative mRNA expression of VEGF was significantly elevated in both low-grade and high-grade EOC. Individuals with the homozygous VEGF rs699947 AA genotype exhibited the highest mRNA expression compared to other genotypes. In contrast, individuals carrying the CC genotype showed the lowest correlation with VEGF mRNA expression in both low-grade and high-grade EOC.

Conclusion: This study shows that the A allele of VEGF rs699947 is correlated with increased VEGF mRNA expression in EOC patients, particularly in those with the AA genotype. Conversely, the C allele may offer a protective effect against EOC, as the CC genotype is linked to lower VEGF mRNA expression. Genetic screening for VEGF rs699947 could facilitate early detection and inform targeted therapeutic strategies.

Note: This article has supplementary file(s).

Fulltext |  Research Instrument
VEGF mRNA Expression in Epithelial Ovarian Cancer: Correlation with rs699947 Gene Variant
Subject
Type Research Instrument
  Download (1MB)    Indexing metadata
 Cover Letter
VEGF mRNA Expression in Epithelial Ovarian Cancer: Correlation with rs699947 Gene Variant
Subject
Type Cover Letter
  Download (51KB)    Indexing metadata
 common.other
VEGF mRNA Expression in Epithelial Ovarian Cancer: Correlation with rs699947 Gene Variant
Subject
Type Other
  Download (3MB)    Indexing metadata
Keywords: Angiogenesis; Epithelial Ovarian Cancer; rs699947; Single Nucleotide Polymorphism; VEGF.

Article Metrics:

Article Info
Section: Original Research Articles
Language : EN
Recent articles
VEGF mRNA Expression in Epithelial Ovarian Cancer: Correlation with rs699947 Gene Variant The Association Between Intake of Saturated, Monounsaturated, and Polyunsaturated Fatty Acids with Bifidobacterium Abundance Among Obese Adults Without Metabolic Syndrome Effect of Umbilical Cord Cell Isolate Administration on STRO-1 and CD 34 Expression of Dental Pulp Stem Cell Culture Detection of Pathogenic Leptospira in Sputum of Leptospirosis Patient with Pulmonary Hemorrhage. More recent articles
  1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;149(4):778–89
  2. Instalasi Pengendali Data Beban Kanker dan Jejaring Kanker Nasional. Profil Kanker RS. Kanker Dharmais. Kemenkes RSK Dharmais. 2020. p. 25
  3. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin [Internet]. 2019 Jul 17;69(4):280–304. Available from: https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21559
  4. González-Martín A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2023 Oct;34(10):833–48. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753423007974
  5. Lorenc P, Sikorska A, Molenda S, Guzniczak N, Dams-Kozlowska H, Florczak A. Physiological and tumor-associated angiogenesis: Key factors and therapy targeting VEGF/VEGFR pathway. Biomed Pharmacother [Internet]. 2024 Nov;180:117585. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0753332224014719
  6. Saman H, Raza SS, Uddin S, Rasul K. Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches. Cancers (Basel) [Internet]. 2020 May 6;12(5):1172. Available from: https://www.mdpi.com/2072-6694/12/5/1172
  7. Pérez-Gutiérrez L, Ferrara N. Biology and therapeutic targeting of vascular endothelial growth factor A. Nat Rev Mol Cell Biol [Internet]. 2023 Nov 25;24(11):816–34. Available from: https://www.nature.com/articles/s41580-023-00631-w
  8. Ye X, Gaucher JF, Vidal M, Broussy S. A Structural Overview of Vascular Endothelial Growth Factors Pharmacological Ligands: From Macromolecules to Designed Peptidomimetics. Molecules [Internet]. 2021 Nov 9;26(22):6759. Available from: https://www.mdpi.com/1420-3049/26/22/6759
  9. Quintero-Fabián S, Arreola R, Becerril-Villanueva E, Torres-Romero JC, Arana-Argáez V, Lara-Riegos J, et al. Role of Matrix Metalloproteinases in Angiogenesis and Cancer. Front Oncol [Internet]. 2019 Dec 6;9. Available from: https://www.frontiersin.org/article/10.3389/fonc.2019.01370/full
  10. Ullah I, Abu-Dawud R, Busch JF, Rabien A, Erguen B, Fischer I, et al. VEGF – Supplemented extracellular matrix is sufficient to induce endothelial differentiation of human iPSC. Biomaterials [Internet]. 2019 Sep;216:119283. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0142961219303825
  11. Wang G, Heij LR, Liu D, Dahl E, LANG SA, Ulmer TF, et al. The Role of Single-Nucleotide Polymorphisms in Cholangiocarcinoma: A Systematic Review. Cancers (Basel) [Internet]. 2022 Dec 2;14(23):5969. Available from: https://www.mdpi.com/2072-6694/14/23/5969
  12. Wu YL, Lin ZJ, Li CC, Lin X, Shan SK, Guo B, et al. Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study. Signal Transduct Target Ther [Internet]. 2023 Mar 2;8(1):98. Available from: https://www.nature.com/articles/s41392-023-01333-7
  13. Suvanto M, Beesley J, Blomqvist C, Chenevix-Trench G, Khan S, Nevanlinna H. SNPs in lncRNA Regions and Breast Cancer Risk. Front Genet [Internet]. 2020 Jun 30;11. Available from: https://www.frontiersin.org/article/10.3389/fgene.2020.00550/full
  14. Bhaskari J, Premalata CS, Shilpa V, Rahul B, Pallavi VR, Ramesh G, et al. Vascular endothelial growth factor polymorphisms and a synchronized examination of plasma and tissue expression in epithelial ovarian cancers. Tumor Biol [Internet]. 2016 Jan 13;37(1):1017–23. Available from: http://link.springer.com/10.1007/s13277-015-3891-3
  15. Al-Mohaya MA, Alfadhel AK, Mustafa M, Alquwayz TS, Al-Anazi MA. Vascular endothelial growth factor (VEGF-2578 C > A) gene polymorphism as a genetic biomarker for breast cancer: A case control study. Gene Reports [Internet]. 2021 Mar;22:101007. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2452014420304210
  16. Xu CH, He ZH, Xu H. Association of four genetic polymorphisms in the vascular endothelial growth factor-A gene and development of ovarian cancer: a meta-analysis. Oncotarget [Internet]. 2017 Sep 22;8(42):73063–78. Available from: https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.20379
  17. Care NI for H and, Excellence. Menopause ( update ) Ovarian Cancer. Vol. 3. National Library of Medicine, NCBI; 2024
  18. Liu Y, Ma L, Yang X, Bie J, Li D, Sun C, et al. Menopausal Hormone Replacement Therapy and the Risk of Ovarian Cancer: A Meta-Analysis. Front Endocrinol (Lausanne) [Internet]. 2019 Dec 3;10. Available from: https://www.frontiersin.org/article/10.3389/fendo.2019.00801/full
  19. Janardhan B, Vaderhobli S, Bhagat R, Chennagiri Srinivasamurthy P, Venketeshiah Reddihalli P, Gawari R, et al. Investigating impact of Vascular Endothelial Growth Factor Polymorphisms in Epithelial Ovarian Cancers: A Study in the Indian Population. Tang CH, editor. PLoS One [Internet]. 2015 Jul 9;10(7):e0131190. Available from: https://dx.plos.org/10.1371/journal.pone.0131190
  20. Herrera-Luis E, Benke K, Volk H, Ladd-Acosta C, Wojcik GL. Gene–environment interactions in human health. Nat Rev Genet [Internet]. 2024 Nov 28;25(11):768–84. Available from: https://www.nature.com/articles/s41576-024-00731-z
  21. Gupta P. Population Genetics. In: Genetics Fundamentals Notes [Internet]. Singapore: Springer Nature Singapore; 2022. p. 1077–103. Available from: https://link.springer.com/10.1007/978-981-16-7041-1_21
  22. Mukherjee S. VEGF Expression to Support Targeted Therapy in Ovarian Surface Epithelial Neoplasms. J Clin Diagnostic Res [Internet]. 2017; Available from: http://jcdr.net/article_fulltext.asp?issn=0973-709x&year=2017&volume=11&issue=4&page=EC43&issn=0973-709x&id=9737
  23. Geindreau M, Ghiringhelli F, Bruchard M. Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response. Int J Mol Sci [Internet]. 2021 May 4;22(9):4871. Available from: https://www.mdpi.com/1422-0067/22/9/4871
  24. He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, et al. Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct Target Ther [Internet]. 2021 Dec 16;6(1):425. Available from: https://www.nature.com/articles/s41392-021-00828-5
  25. Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther [Internet]. 2023 Feb 17;8(1):70. Available from: https://www.nature.com/articles/s41392-023-01332-8
  26. Emami Nejad A, Najafgholian S, Rostami A, Sistani A, Shojaeifar S, Esparvarinha M, et al. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int [Internet]. 2021 Jan 20;21(1):62. Available from: https://cancerci.biomedcentral.com/articles/10.1186/s12935-020-01719-5
  27. Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach J V. Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy. Clin Cancer Res [Internet]. 2023 Jan 4;29(1):30–9. Available from: https://aacrjournals.org/clincancerres/article/29/1/30/711982/Molecular-Mechanisms-and-Future-Implications-of
  28. de Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell [Internet]. 2023 Mar;41(3):374–403. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1535610823000442
  29. Shaw P, Dwivedi SKD, Bhattacharya R, Mukherjee P, Rao G. VEGF signaling: Role in angiogenesis and beyond. Biochim Biophys Acta - Rev Cancer [Internet]. 2024 Mar;1879(2):189079. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0304419X24000106
  30. Santoro A, Angelico G, Travaglino A, Inzani F, Spadola S, Pettinato A, et al. The multiple facets of ovarian high grade serous carcinoma: A review on morphological, immunohistochemical and molecular features. Crit Rev Oncol Hematol [Internet]. 2025 Apr;208:104603. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1040842824003469
  31. Li AM, Boichard A, Kurzrock R. Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues. Cancer Biol Ther [Internet]. 2020 Jan 2;21(1):95–100. Available from: https://www.tandfonline.com/doi/full/10.1080/15384047.2019.1665956
  32. Ruzzo A, Graziano F, Palladino S, Fischer NW, Catalano V, Giordani P, et al. Clinical impact of TP53 functional mutations in patients with metastatic colorectal cancer treated with bevacizumab and chemotherapy. Oncologist [Internet]. 2024 Oct 22; Available from: https://academic.oup.com/oncolo/advance-article/doi/10.1093/oncolo/oyae277/7831369
  33. Chionh F, Gebski V, Al-Obaidi SJ, Mooi JK, Bruhn MA, Lee CK, et al. VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer. Sci Rep [Internet]. 2022 Jan 24;12(1):1238. Available from: https://www.nature.com/articles/s41598-021-03952-y
  34. Palmer BR, Paterson MA, Frampton CM, Pilbrow AP, Skelton L, Pemberton CJ, et al. Vascular endothelial growth factor-A promoter polymorphisms, circulating VEGF-A and survival in acute coronary syndromes. Zirlik A, editor. PLoS One [Internet]. 2021 Jul 14;16(7):e0254206. Available from: https://dx.plos.org/10.1371/journal.pone.0254206

Last update:

No citation recorded.

Last update:

No citation recorded.